PMC5554992_01
Axial contrast enhanced CT at the level of the mid-oesophagus (a) demonstrates a circumferential soft tissue oesophageal mass with increased metabolic activity (SUVmax 15.0) on the PET component of the study (c). Axial contrast enhanced CT at the level of the gastroesophageal junction (b) demonstrates soft tissue thickening surrounding the gastric stent in situ. The PET component of the study (c) at this level shows increased FDG avidity (SUVmax 14.2) consistent with a second tumour. Incidental note of a FDG avid left thyroid nodule.
CRIGM2017-2713589.002.jpg
PMC5554992_01_CRIGM2017-2713589.002.jpg
fig2
Large metabolically active lymph nodes at the level of the celiac axis measuring up to 15 mm were evident with a maximum SUV of 4.5 (Figure 2).
Invasive high grade squamous cell carcinoma.
CRIGM2017-2713589.003.jpg
PMC5554992_01_CRIGM2017-2713589.003.jpg
fig3
Specimen A from the mid-oesophagus showed high grade carcinoma with some features suggesting neuroendocrine differentiation (Figure 3).
SCC positive for P63, CK 5/6, and CAM5.2.
CRIGM2017-2713589.004.jpg
PMC5554992_01_CRIGM2017-2713589.004.jpg
fig4
Immunohistochemistry showed positive staining for CK 5/6, P63, and CAM 5.2 confirming a diagnosis of SCC (Figure 4).
Invasive moderately differentiated mucinous adenocarcinoma.
CRIGM2017-2713589.005.jpg
PMC5554992_01_CRIGM2017-2713589.005.jpg
fig5
Lower oesophageal mass prior to stenting.
CRIGM2017-2713589.006.jpg
PMC5554992_01_CRIGM2017-2713589.006.jpg
fig6
Progressive dysphagia warranted a repeat OGD with the insertion of an oesophageal stent.  Figure 6 demonstrates the lower oesophageal mass prior to stenting.
Lower oesophagus poststenting.
CRIGM2017-2713589.007.jpg
PMC5554992_01_CRIGM2017-2713589.007.jpg
fig7
A 12 cm partially covered Wallflex stent was placed across the lower malignancy (Figure 7).